Response to tetanus toxoid immunization after allogeneic bone marrow transplantation.

An ELISA was used to study long-term immunity and immunization responses to tetanus toxoid in 48 bone marrow transplant recipients. Among patients who were seropositive to tetanus before transplant, 51% had lost their seropositivity 1 year later. All patients who were not reimmunized with tetanus toxoid were seronegative 2 years after transplant. All patients who were seronegative before transplant remained seronegative 1 year later regardless of the donor's serologic status. There was no difference in the ability to remain seropositive to tetanus toxoid between patients with and without chronic graft-versus-host disease. Of 21 patients immunized with one dose of tetanus toxoid 1 year after transplant, 14 were seronegative at the time of immunization (response rate, 64%). At 1 year after immunization, 7 remained seropositive. Ten patients were reimmunized with two doses of tetanus toxoid. All responded and 90% remained seropositive 1 year later. When 21 patients were primarily immunized with three doses of tetanus toxoid, all patients seronegative at immunization responded and all tested patients remained seropositive 2 years later. The immunization responses were significantly superior in patients receiving three doses compared with those who received one. Reimmunization with tetanus toxoid of long-term survivors after marrow transplant seems necessary. A three-dose immunization schedule is recommended to obtain an adequate immune response.

[1]  G. Gahrton,et al.  Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. , 1989, The Journal of infectious diseases.

[2]  K. Sullivan,et al.  Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. , 1988, Bone marrow transplantation.

[3]  H. Deeg,et al.  Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. , 1987, Transplantation proceedings.

[4]  O. Ringdén,et al.  Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. , 1987, Bone marrow transplantation.

[5]  L. Lum The kinetics of immune reconstitution after human marrow transplantation. , 1987, Blood.

[6]  R. Gale,et al.  Designed transfer of specific immune responses with bone marrow transplantation. , 1986, The Journal of clinical investigation.

[7]  G. Gahrton,et al.  A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. , 1986, Bone marrow transplantation.

[8]  R. Storb,et al.  The detection of specific antibody formation to recall antigens after human bone marrow transplantation. , 1986, Blood.

[9]  H. Prentice,et al.  TRANSFER OF A FUNCTIONING HUMORAL IMMUNE SYSTEM IN TRANSPLANTATION OF T-LYMPHOCYTE-DEPLETED BONE MARROW , 1986, The Lancet.

[10]  L. Hammarström,et al.  Enzyme-linked immunosorbent assay for subclass distribution of human IgG and IgA antigen-specific antibodies. , 1985, Journal of immunological methods.

[11]  G. Gahrton,et al.  Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. , 1984, The Journal of infectious diseases.

[12]  K. Sullivan,et al.  Oral manifestations of chronic graft-v-host disease. , 1984, Archives of internal medicine.

[13]  G. Janossy,et al.  DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTS , 1984, The Lancet.

[14]  H. Deeg,et al.  RECOVERY OF IN VIVO CELLULAR IMMUNITY AFTER HUMAN MARROW GRAFTING: Influence of Time Postgrafting and Acute Graft‐Versus‐Host Disease , 1984, Transplantation.

[15]  B. Johansson,et al.  EXPERIENCE WITH A COOPERATIVE BONE MARROW TRANSPLANTATION PROGRAM IN STOCKHOLM , 1982, Transplantation.